Received: 11 August 2018
Accepted: 31 October 2018
First Online: 14 November 2018
Ethics approval and consent to participate
: This study received approval and consent from the competent Institutional Review Board, namely, <i>Comité de Ética de la Investigación de Almería</i> (Ethics Research Committee of Almeria) on the 1st January 2017, protocol number EPA-E-JAC-2016 version 1. The need for consent was deemed unnecessary by this IRB because the study was carried out within usual clinical practice.
: Not applicable.
: JSC participated on one advisory board for Gilead Sciences and received travel grants from Gilead Sciences and Bristol-Myers Squibb. ABLS participated on advisory boards for Bristol-Myers Squibb, and reports travel funding, educational grants and speaker fees from GlaxoSmithKline (ViiV Healthcare), Gilead Sciences, Tibotec (Janssen) Therapeutics, Abbie, Merck Sharp and Dohme, BoehringerIngelheim, Roche Pharma, Pfizer, and Bristol-Myers Squibb. JACG, MJSP and JVV received travel grants from Gilead Sciences. MEE received speaker fees and/or travel funding from Gilead Sciences, Bristol-Myers Squibb, Abbie, Merck Sharp and Dohme. All other authors declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.